This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- l (Previously presented): A solid pharmaceutical composition for oral administration comprising a granulation, said granulation comprising
- rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid,
- a water soluble polymer in an amount of about 1 % to about 40% (wt/wt),
- a surfactant in an amount of about 1 % to about 8% (wt/wt), an antioxidant from 0.001% to 3% (wt/wt), and a pH modifying agent.
- 2 (Original): The composition of claim 1, wherein the water soluble polymer is PVP, hydroxypropylmethylcellulose, polyethylene glycol, or cyclodextrin or mixtures thereof.
- 3 (Original): The composition of claim 2, wherein the water soluble polymer is PVP.
- 4 (Previously presented): The composition of claim 1, wherein the surfactant is polysorbate 80, sodium lauryl sulfate, sodium dodecyl sulfate, a salt of a bile acid, an ethoxylated vegetable oil, a polyoxyethylene-polyoxypropylene block copolymer, or a poloxamer.
- 5 (Original): The composition of claim 4, wherein the surfactant is sodium lauryl sulfate or sodium dodecyl sulfate.

US Patent Application No. 10/663,506 Response to Office Action dated October 17, 2007

6 (Previously presented): The pharmaceutical composition of claim 1, wherein the pH modifying agent is sodium citrate, citric acid, or dilute hydrochloric acid.

Claims 7 - 9 (Cancelled).

- 10 (Previously presented): A rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid oral composition prepared by the process comprising:
 - (a) dissolving rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and from 0.001% to 3% (wt/wt) of an antioxidant in an alcohol;
 - (b) dissolving PVP, a pH modifying agent, and a surfactant in water:
 - (c) combining the aqueous and alcoholic solutions to provide a hydroholic solution;
 - (d) adding the hydroalcoholic solution to a mixer containing one or more intragranular excipients;
 - (e) granulating the mixture; and
 - (f) drying the resulting granulation.
- 11 (Original): The composition of claim 10, wherein the pH modifying agent is selected from the group consisting of citric acid, sodium citrate, hydrochloric acid and mixtures thereof.
 - 12 (Original): The composition of claim 11, wherein the alcohol is ethanol.
- 13 (Original): The composition of claim 12, wherein the antioxidant is butylated hydroxyanisole and butylated hydroxytoluene.
- 14 (Original): The composition of claim 13, wherein the surfactant is sodium lauryl sulfate.

- 15 (Previously presented): A rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid oral formulation prepared by the process comprising:
 - (a) dissolving rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and from 0.001% to 3% (wt/wt) of an antioxidant in an alcohol;
 - (b) dissolving PVP, a pH modifying agent, and a surfactant in water:
 - adding the aqueous and alcoholic solutions stepwise, and in one or more portions each, to a mixer containing one or more intragranular excipients;
 - (d) granulating the mixture; and
 - (e) drying the resulting granulation.
- 16 (Original): The composition of claim 15, wherein the pH modifying agent is selected from the group consisting of citric acid, sodium citrate, hydrochloric acid and mixtures thereof.
 - 17 (Original): The composition of claim 16, wherein the alcohol is ethanol.
- 18 (Original): The composition of claim 17, wherein the antioxidant is butylated hydroxyanisole and butylated hydroxytoluene.
- 19 (Original): The composition of claim 18, wherein the surfactant is sodium lauryl sulfate.

US Patent Application No. 10/663,506 Response to Office Action dated October 17, 2007

20 (Previously presented): The pharmaceutical composition according to claim 1, comprising rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid present in an amount of about 1% (wt/wt) to about 5% (wt/wt), polyvinylpyrrolidone in an amount of about 5% (wt/wt) to about 20% (wt/wt);

a surfactant comprising sodium laurel sulfate in an amount of about 3% to about 5% (wt/wt), and citric acid.